METTL14 promotes lipid metabolism and inhibits atherogenesis by activating PPAR-α/γ expression and fatty acid oxidation in vascular smooth muscle cells.
The endogenous METTL14/PPAR-α/γ axis represents a potential therapeutic target for treating atherosclerotic and metabolic diseases.
We have unveiled that METTL14 promotes lipid metabolism and inhibits atherogenesis through activating PPAR-α/γ expression. These experiments highlight the therapeutic potential of the endogenous METTL14/PPAR-α/γ axis for treating atherosclerotic and metabolic diseases.
Cui et al. (2026) studied this question. METTL14 promotes lipid metabolism and inhibits atherogenesis by activating PPAR-α/γ expression and fatty acid oxidation in vascular smooth muscle cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: